Table 1.
Weighted* time-varying characteristics and late life brain volumes of eligible ARIC-NCS participants
| Visit 1(~24 years prior to MRI) |
Visit 4 (~15 years prior to MRI) |
Visit 5 (Concurrent with MRI) |
|
|---|---|---|---|
| Mean (25th, 75th percentile) or % | |||
| Time to MRI (years) | 24 (23, 24) | 15 (14, 15) | 0 (0, 0) |
| Age (years) | 52 (47, 55) | 61 (56, 64) | 75 (70, 79) |
| Body mass index | |||
| Normal | 40% | 28% | 28% |
| Overweight | 38% | 40% | 40% |
| Obese | 22% | 33% | 33% |
| Smoking status | |||
| Current | 16% | 9% | 5% |
| Former | 32% | 47% | 51% |
| Never | 52% | 43% | 44% |
| Diabetes | 4% | 10% | 31% |
| Hypercholesterolemia | 58% | 50% | 35% |
| Systolic blood pressure (mmHg) | 115 (103, 122) | 123 (111, 132) | 130 (117, 140) |
| Diastolic blood pressure (mmHg) | 72 (65, 78) | 71 (64, 77) | 66 (58, 72) |
| Pulse pressure (mmHg) | 43 (35, 48) | 52 (42, 59) | 64 (54, 72) |
| History of hypertension | 31% | 53% | 81% |
| Antihypertensive medication use | 19% | 32% | 72% |
| Beta blockers** | 6% | 8% | 29% |
| Calcium channel blockers** | 2% | 9% | 22% |
| ACE Inhibitors/ARBs** | 2% | 11% | 44% |
| Diuretics** | 12% | 14% | 40% |
| Measured blood pressure | |||
| Hypotensive | 9% | 11% | 28% |
| Normotensive | 83% | 73% | 49% |
| Hypertensive | 8% | 16% | 23% |
| Estimated intracranial volume (cm3) | -- | -- | 1387 (1275, 1488) |
| Total brain volume (cm3) | -- | -- | 1026 (949, 1099) |
| Temporal lobe cortical volume (cm3) | -- | -- | 103 (96, 111) |
| Parietal lobe cortical volume (cm3) | -- | -- | 108 (99, 116) |
| Occipital lobe cortical volume (cm3) | -- | -- | 41 (38, 45) |
| Frontal lobe cortical volume (cm3) | -- | -- | 152 (141, 162) |
| Deep grey matter (cm3) | -- | -- | 43 (40, 45) |
| AD signature region volume (cm3) | -- | -- | 60 (55, 64) |
Abbreviations: ACE, angiotension-converting enzyme; AD, Alzheimer’s disease; ARB, angiotension receptor blockers; ARIC-NCS Atherosclerosis Risk in Communities Neurocognitive Study
*
Weighting was used to account for the sampling strategy used to select Visit 5 participants for MRI.
**
Not mutually exclusive